Zdrowie i gospodarka · 29/10/1997

FDA to Host Public Workshop on Biologics License Application for Blood Products and Changes to Approved Applications

The U.S. Food and Drug Administration (FDA) will host a public workshop to discuss its biologics license application for blood products and any changes to previously approved applications, following the submission of a new application by a pharmaceutical company, Pfizer, for its blood clotting treatment, Xarelto.